Skip to content

Psychedelic treatment for headache disorders.

Erik Zorrilla, Emmanuelle A D Schindler

Nature reviews. Neurology November 17, 2026 DOI: 10.1038/s41582-026-01285-w (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Perspective Peer reviewed
Interventions Psilocybin dimethyltryptamine lysergic acid diethylamide
Key points Argues that psychedelic drugs, especially psilocybin, are re-emerging as potential transitional treatments for cluster headache and migraine, with clinical trials supporting reported efficacy and safety, and that patient advocacy has driven renewed interest. The authors emphasize that evidence remains limited and that safety, logistical, and legal concerns must be addressed in future research.

Abstract

Headache disorders are common neurological conditions with numerous treatment options depending on the specific disorder and the needs of the individual. Psychedelic drugs, such as psilocybin, dimethyltryptamine and lysergic acid diethylamide, have important historical roles in headache medicine and are re-emerging as potential therapeutic options, particularly in cluster headache. The renewed interest in psychedelic treatment for headache is largely attributable to the patient community, who have advocated for their preferred forms of treatment, including psychedelic drugs. Clinical trials in cluster headache and migraine have supported the reported efficacy and safety of psilocybin in the transitional treatment of these disorders, and additional studies of other compounds and modes of treatment are ongoing or on the horizon. In this Perspective, we provide an overview of psychedelic drugs in headache medicine, including historical context, relationship to conventional headache medications, and the limited clinical and scientific evidence to date. Safety, logistical and legal concerns are also discussed to set the stage for future work in the field.